Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis

BackgroundInefficient transduction is a major limitation in achieving therapeutic levels of AAV-delivered microdystrophin capable of improving muscle function in patients with Duchenne muscular dystrophy. Additionally, some patients experience acute complications due to activation of innate immune p...

Full description

Bibliographic Details

Main Authors:	Rita Spathis, Deeva Robles Kuriplach, Sabrina Narvesen, Matthew Eybs, Karen Huang, Steven Torres, Madison King, Elizabeth Bagley, Pia Elustondo, Michael W. Lawlor, Kanneboyina Nagaraju, Melissa Morales
Format:	Artigo
Language:	Inglês
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Immunology
Subjects:	AAV9 mdx Duchenne muscular dystrophy DMD gene therapy immune response
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1527840/full
Tags:	Add Tag No Tags, Be the first to tag this record!